BioSpace podcast

The untapped potential of drug repurposing

19/11/2026
0:00
19:10
Manda indietro di 15 secondi
Manda avanti di 15 secondi

In this episode of Denatured, I speak with Daniel Tillett, CEO of Racura Oncology and Sten Sörensen, CEO of Cereno Scientific. We explore why the FDA is now prioritizing drug repurposing, and what it will take to turn existing molecules into viable new therapies.

Host

Jennifer C. Smith-Parker, Director of Insights, BioSpace

Guests

Daniel Tillett, CEO, Racura Oncology

Sten Sörensen, CEO, Cereno Scientific

Disclaimer: The views expressed in this discussion by guests are their own and do not represent those of their organizations.


Altri episodi di "BioSpace"